Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22375970

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2012 Mar 1
First author
Harrison C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2012 Mar 1;366(9):844-6. doi: 10.1056/NEJMe1115119.
    note
    Source null
    related pmid
    22375977
    relationship
    Comment in
  2. citation
    N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
    note
    Source null
    related pmid
    22621633
    relationship
    Comment in
  3. citation
    N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
    note
    Source null
    related pmid
    22621634
    relationship
    Comment in
  4. citation
    N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
    note
    Source null
    related pmid
    22621635
    relationship
    Comment in

Authors and identifiers

  1. name
    Harrison C
    type
    Author
  2. name
    Kiladjian JJ
    type
    Author
  3. name
    Al-Ali HK
    type
    Author
  4. name
    Gisslinger H
    type
    Author
  5. name
    Waltzman R
    type
    Author
  6. name
    Stalbovskaya V
    type
    Author
  7. name
    McQuitty M
    type
    Author
  8. name
    Hunter DS
    type
    Author
  9. name
    Levy R
    type
    Author
  10. name
    Knoops L
    type
    Author
  11. name
    Cervantes F
    type
    Author
  12. name
    Vannucchi AM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Harrison C
    type
    Author
  2. name
    Kiladjian JJ
    type
    Author
  3. name
    Al-Ali HK
    type
    Author
  4. name
    Gisslinger H
    type
    Author
  5. name
    Waltzman R
    type
    Author
  6. name
    Stalbovskaya V
    type
    Author
  7. name
    McQuitty M
    type
    Author
  8. name
    Hunter DS
    type
    Author
  9. name
    Levy R
    type
    Author
  10. name
    Knoops L
    type
    Author
  11. name
    Cervantes F
    type
    Author
  12. name
    Vannucchi AM
    type
    Author
bibliography ids
  1. nci-bib-09353123772f4e4d3c73b50e
book metadata
content sha256
2e8a94f01579485169df851e2b3d9b8b75006bfe52b2a9dd8eefa41de11cbd96
document type
citation
dois
  1. 10.1056/NEJMoa1110556
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:22375970
immutable id
pubmed:22375970@2e8a94f01579485169df851e2b3d9b8b75006bfe52b2a9dd8eefa41de11cbd96
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
9
name
The New England journal of medicine
nlm unique id
0255562
pages
787-98
volume
366
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2012 Mar 1;366(9):844-6. doi: 10.1056/NEJMe1115119.
    note
    Source null
    related pmid
    22375977
    relationship
    Comment in
  2. citation
    N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
    note
    Source null
    related pmid
    22621633
    relationship
    Comment in
  3. citation
    N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
    note
    Source null
    related pmid
    22621634
    relationship
    Comment in
  4. citation
    N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
    note
    Source null
    related pmid
    22621635
    relationship
    Comment in
outcomes validated
false
pmid
22375970
provenance
batch id
b6284687e167e7da9556
provider
NCBI PubMed ESummary
record sha256
8f77e95888259fe4a37a7018b5dd9c8c35936e50a67c66a4f21f35e2023f801d
response sha256
64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
retrieved at
2026-09-09T23:46:45.216259+00:00
publication date
display
2012 Mar 1
precision
day
year
2012
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22375970/
title
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Preserved source evidence · Not medical advice